Provided by Tiger Trade Technology Pte. Ltd.

Harmony Biosciences Holdings, Inc.

27.81
-0.0400-0.14%
Post-market: 28.150.3400+1.22%16:32 EDT
Volume:776.19K
Turnover:21.48M
Market Cap:1.60B
PE:10.26
High:28.16
Open:27.67
Low:27.11
Close:27.85
52wk High:40.87
52wk Low:25.52
Shares:57.60M
Float Shares:44.56M
Volume Ratio:1.30
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.71
EPS(LYR):2.71
ROE:20.75%
ROA:11.48%
PB:1.84
PE(LYR):10.26

Loading ...

Harmony Says FDA Approves Wakix for Cataplexy in Children With Narcolepsy

MT Newswires Live
·
Feb 17

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for Wakix® (Pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

THOMSON REUTERS
·
Feb 17

Earning Preview: Harmony Biosciences Holdings, Inc. this quarter’s revenue is expected to increase by 19.55%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 17

Harmony Biosciences Cut to Neutral From Buy by UBS

Dow Jones
·
Feb 11

Harmony Biosciences Holdings Inc. to Report Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Feb 10

Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares

Reuters
·
Jan 29

Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares

Reuters
·
Jan 21

Harmony Biosciences : Needham Raises Target Price to $46 From $42

THOMSON REUTERS
·
Jan 20

Harmony Biosciences Holdings (HRMY) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Jan 13

BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation

Reuters
·
Jan 12

Harmony Biosciences Q4 Prelim Unaudited Net Product Revenue $243 Mln

THOMSON REUTERS
·
Jan 12

Harmony Biosciences: Wakix Net Revenue Projected Between $1.0 Bln - $1.04 Bln for 2026

THOMSON REUTERS
·
Jan 12

Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026

Reuters
·
Jan 12

Harmony Biosciences Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 09

Harmony Biosciences price target lowered to $45 from $48 at Truist

TIPRANKS
·
Jan 08

Harmony Biosciences to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 07

Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares

Reuters
·
Dec 18, 2025

BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences

Reuters
·
Dec 16, 2025

Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials

Reuters
·
Dec 16, 2025

Beacon Biosignals Announces Partnership With Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative Eeg

THOMSON REUTERS
·
Dec 16, 2025